As September marks the beginning of Pain Awareness Month, Adalvo highlights its commitment to addressing one of the world’s most prevalent and challenging healthcare burdens. Chronic pain affects millions globally, often leading to diminished quality of life, reduced productivity, and limited treatment options.
Through our expanding pain management portfolio, Adalvo continues to deliver partner-ready, high-value therapies designed to improve patient access and support healthcare providers in tackling complex treatment needs.
Key highlights from Adalvo’s pain portfolio include:
- Gabapentin ER – Successfully launched in South Korea, extending treatment options for patients requiring long-term management of neuropathic pain.
- Pregabalin ER – The first and only prolonged-release pregabalin launched across Europe, offering a simplified, once-daily dosing alternative for neuropathic pain while reducing patient burden.
- Fentanyl (Onsolis®) – European launch planned for Q4 2025, providing a differentiated treatment option for breakthrough cancer pain in opioid-tolerant patients.
- Clobetasol – A proven therapy within Adalvo’s portfolio, supporting effective pain control and representing another cornerstone of the company’s dedication to this therapeutic area.
By combining a clear IP strategy, strong regulatory execution, and technical expertise, Adalvo is enabling partners to bring difficult-to-develop pain therapies to patients faster, addressing an area of significant unmet medical need.
Adalvo also addresses the synergy between pain and oncology by integrating tumour-directed therapies with evidence-based analgesic strategies, optimising both disease control and symptom burden reduction for improved patient outcomes. Our rich first-to-market oncology portfolio offers 30+ opportunities, further strengthening Adalvo’s position as a global B2B leader
Adalvo will continue to expand its footprint in pain management, with additional launches and lifecycle strategies planned across global markets.
To explore partnership opportunities within Adalvo’s pain portfolio, contact the team today.